| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10555902 | CYCLE | Stable fingolimod dosage forms |
Jan, 2036
(11 years from now) | |
| US9925138 | CYCLE | Stable solid fingolimod dosage forms |
Jan, 2036
(11 years from now) | |
| US10925829 | CYCLE | Stable solid fingolimod dosage forms |
Jan, 2036
(11 years from now) | |
Tascenso Odt is owned by Cycle.
Tascenso Odt contains Fingolimod Lauryl Sulfate.
Tascenso Odt has a total of 3 drug patents out of which 0 drug patents have expired.
Tascenso Odt was authorised for market use on 23 December, 2021.
Tascenso Odt is available in tablet, orally disintegrating;oral dosage forms.
Tascenso Odt can be used as the treatment of relapsing forms of multiple sclerosis (ms) in patients 10 years of age and older.
The generics of Tascenso Odt are possible to be released after 19 January, 2036.
Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient
Market Authorisation Date: 23 December, 2021
Treatment: The treatment of relapsing forms of multiple sclerosis (ms) in patients 10 years of age and older
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
TASCENSO ODT family patents
